Paradoxically Increased Ferritin Level in a Beta-Thalassemia Major Patient following the Start of Deferasirox Chelation Therapy

Publisher： Karger

E-ISSN： 1421-9662|123|2|117-120

ISSN： 0001-5792

Source： Acta Haematologica, Vol.123, Iss.2, 2010-01, pp. : 117-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Evaluation of the Incidence of Sensorineural Hearing Loss in Beta-Thalassemia major Patients under Regular Chelation Therapy with Desferrioxamine

By  

Acta Haematologica, Vol. 108, Iss. 2, 2002-08 ,pp. : 79-83

Karger

Access to resources Recommend Favorite

Deferiprone Chelation Therapy for Thalassemia Major

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 155-164

Karger

Access to resources Recommend Favorite

Increased Serum Heat Shock Protein 27 Antibody Titers and Prooxidant-Antioxidant Balance in Patients with Beta-Thalassemia Major

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

Immunological Evaluation of Patients with Beta-Thalassemia major

By  

Acta Haematologica, Vol. 105, Iss. 1, 2001-04 ,pp. : 7-12

Karger

Access to resources Recommend Favorite